Most recruitment efforts focus on identifying eligible patients—but fail to identify those who are willing to respond to outreach.

Social intelligence identifies patients actively discussing their condition, seeking advice, and demonstrating openness to engagement—allowing recruitment strategies to focus on audiences more likely to convert.

Without this behavioral layer, trials risk targeting large populations with low response rates, increasing timelines and recruitment costs.

Clinical trial messaging is often built around protocol requirements rather than patient concerns.

Social intelligence reveals how patients describe their condition, what concerns they prioritize, and what drives their decision-making—allowing communication strategies to align with real-world patient perspectives.

Without this understanding, outreach may be seen, but ignored.

Patients often discuss symptoms, side effects, and concerns in real-world environments before—or instead of—formal reporting pathways.

Social intelligence provides real-time visibility into these conversations, identifying early signals of adverse events, confusion, or dissatisfaction that may impact safety, compliance, and retention.

Without this visibility, critical signals may be delayed or missed entirely.

Clinical and claims data provide information about eligibility—but not about how patients behave, make decisions, or evaluate participation.

Social intelligence captures real-world behaviors, preferences, and lifestyle factors that influence recruitment and retention outcomes.

Without this insight, trial design and communication strategies risk being misaligned with patient expectations.

Decisions around protocol design, site selection, and patient engagement are often based on incomplete data.

Social intelligence provides insight into patient sentiment, treatment perception, and behavioral trends—informing decisions that directly impact recruitment success and overall trial performance.

Without this layer, even well-informed strategies can produce inconsistent results.

Safira Social Intelligence analyzes only publicly available social and digital content and does not access or process private, protected, or personally identifiable health information (PHI).

Because the data is public and aggregated, our approach is designed to align with global data privacy frameworks, including GDPR and CCPA, and does not fall under HIPAA-regulated data handling.

All data is collected and analyzed in accordance with platform Terms of Use and applicable data-sharing policies.

This ensures that insights into patient behavior, sentiment, and engagement can be generated without introducing regulatory or compliance risk.

This approach allows organizations to gain meaningful patient insights without introducing additional regulatory burden.

Social intelligence data is collected globally across public digital platforms, enabling analysis of patient behavior, sentiment, and engagement across regions, cultures, and healthcare systems.

This allows clinical trial teams to identify geographic differences in recruitment potential, patient perception, and engagement patterns—critical for site selection and global study planning.

Data coverage excludes restricted regions such as China and North Korea, with native-language analysis and translation available for most markets.

Safira Social Intelligence aggregates data from major public digital platforms, including Facebook, Instagram, YouTube, Reddit, X (Twitter), blogs, forums, and other publicly accessible web sources.

This broad access provides a comprehensive view of how patients, caregivers, and communities discuss health conditions, treatments, and clinical trials—capturing behaviors and perspectives not visible in traditional clinical or claims data.

Social intelligence combines historical and near real-time data to provide both trend analysis and immediate visibility into emerging patient conversations.

Historical data (up to 27 months) allows for identification of long-term patterns in patient behavior, sentiment, and treatment perception.

Near real-time data (within minutes) enables early detection of shifts in patient sentiment, emerging concerns, and potential safety or engagement risks—supporting more responsive clinical trial strategies.

Safira Social Intelligence insights are delivered through both structured reports and interactive dashboards, depending on the needs of the study or organization.

Reports translate patient behavior, sentiment, and engagement patterns into clear, actionable recommendations for clinical trial recruitment, messaging, and strategy.

Live dashboards provide ongoing visibility into patient conversations and trends, allowing teams to monitor changes and adapt strategies as needed.

Social intelligence captures both demographic and behavioral data to provide a comprehensive view of patient populations.

Demographic data includes:
Age, gender, geography, language, and other population-level characteristics.

Behavioral and psychographic data includes:
Patient sentiment, emotions, concerns, preferences, engagement patterns, treatment experiences, and decision-making drivers.

This combination allows clinical trial teams to move beyond identifying eligible patients—and instead understand which patients are most likely to engage and participate.